BioPharmSignal logoBioPharmSignal

Biotech News

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics (INTS)Intensity Therapeutics2026-06-25 13:46 ESTCompany update

INTS (INTS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ints.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics Announces Reverse Stock Split

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

INTSIntensity Therapeutics2026-06-25 13:46 EST

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

View all latest news

Intensity Therapeutics

Intensity Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

INTSIntensity Therapeutics2026-06-26 08:27 EST

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

INTSIntensity Therapeutics2026-06-26 08:27 EST

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

INTSIntensity Therapeutics2026-06-26 08:27 EST

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

INTSIntensity Therapeutics2026-06-26 08:27 EST

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

INTSIntensity Therapeutics2026-06-26 08:27 EST

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States